The hemp boom of recent years has led to a flood of CBD products. Hundreds of brands have entered the market, focusing on mass production and rapid growth. CBD is now ubiquitous in oils, gummies, cosmetic products, and beverages. Yet while many companies continue riding the same waves, others are asking: What comes after CBD? These forward-thinking considerations led to the founding of Rare Cannabinoid Company in Hawaii. The company, founded by Jennifer Carlile and Jared Dalgamouni, focuses not only on CBD but also explores lesser-known cannabinoids that are increasingly capturing the interest of consumers and the industry.
The founders began their journey in 2017 with Hawaiian Choice, their original brand for broad-spectrum CBD products made from locally cultivated hemp. From the outset, they understood that innovation and quality are key to long-term success. Rather than chasing short-term trends, they invested in research and development. This strategy is paying off: Rare Cannabinoid Company is positioning itself as a pioneer in a growing market that extends beyond established CBD products, offering consumers new and diverse options.
This development demonstrates an important trend in the cannabinoid industry – moving away from mass-market products toward innovation and specialization. For Swiss consumers, this means more choice in high-quality products that meet legal requirements. For more information on this exciting industry development, see the original article on High Times.
